CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 59 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6 | +50.0% | 199 | 0.0% | 0.00% | – |
| Q2 2023 | $4 | +33.3% | 199 | 0.0% | 0.00% | – |
| Q1 2023 | $3 | -25.0% | 199 | 0.0% | 0.00% | – |
| Q4 2022 | $4 | -99.9% | 199 | 0.0% | 0.00% | – |
| Q3 2022 | $4,000 | 0.0% | 199 | 0.0% | 0.00% | – |
| Q2 2022 | $4,000 | +33.3% | 199 | +50.8% | 0.00% | – |
| Q1 2022 | $3,000 | -25.0% | 132 | 0.0% | 0.00% | – |
| Q4 2021 | $4,000 | +33.3% | 132 | 0.0% | 0.00% | – |
| Q3 2021 | $3,000 | +200.0% | 132 | +112.9% | 0.00% | – |
| Q2 2021 | $1,000 | 0.0% | 62 | 0.0% | 0.00% | – |
| Q1 2021 | $1,000 | 0.0% | 62 | 0.0% | 0.00% | – |
| Q4 2020 | $1,000 | -50.0% | 62 | -59.5% | 0.00% | – |
| Q3 2019 | $2,000 | -50.0% | 153 | 0.0% | 0.00% | – |
| Q2 2019 | $4,000 | +33.3% | 153 | 0.0% | 0.00% | – |
| Q1 2019 | $3,000 | -57.1% | 153 | -30.5% | 0.00% | – |
| Q4 2018 | $7,000 | – | 220 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |